2023 World Conference on Lung Cancer (Posters)-EP04.01. The PneuVision Test Detects Both Lung Squamous Cell Carcinoma and Adenocarcinoma from Cells in Sputum

EP04.01. The PneuVision Test Detects Both Lung Squamous Cell Carcinoma and Adenocarcinoma from Cells in Sputum - PDF(Abstract)

Back to course

Pdf Summary

The study presents the PneuVision test, which is a screening tool for the early detection of non-small cell lung cancer (NSCLC). The test involves collecting a patient's sputum from home and analyzing the cells in 3D using the Cell-CT platform. The cells are classified using machine learning algorithms to detect abnormal cells indicative of NSCLC. The test has high accuracy, with a sensitivity exceeding 90% for biopsy-confirmed early-stage cancer and near-perfect specificity. <br /><br />In this study, the researchers examined the sensitivity of the PneuVision test specifically for squamous cell carcinoma and adenocarcinoma, two common types of NSCLC. They analyzed sputum samples from patients with biopsy-confirmed cases of these cancers. The analysis was normalized by the enumeration of normal bronchial epithelial cells (BECs) automatically detected by the Cell-CT. Abnormal cells were confirmed by cytologists.<br /><br />The results showed that the sensitivity of the test varied depending on the number of BECs processed and the type of cancer. For a desired sensitivity of 90% for squamous cell carcinoma, at least 1000 BECs should be processed. With this optimization, the detection sensitivity for adenocarcinoma would be approximately 83%.<br /><br />Based on these findings, the researchers concluded that sensitivity increases as more cells from the bronchial epithelium are processed, and the sensitivity increases more rapidly for squamous cell carcinoma compared to adenocarcinoma. They suggest that if the sensitivity for adenocarcinoma is set at an acceptable level, the sensitivity for squamous cell carcinoma would exceed that level.<br /><br />Overall, the PneuVision test shows promise for the detection of NSCLC, particularly in early-stage cases. It has high accuracy and can differentiate between different types of NSCLC. Further research and optimization are needed to improve the detection sensitivity for adenocarcinoma.

Asset Subtitle

Michael Meyer

Meta Tag

Speaker Michael Meyer

Topic Screening & Early Detection: Biomarkers/Imaging Technology

Keywords

PneuVision test

non-small cell lung cancer

NSCLC

early detection

sputum analysis

Cell-CT platform

machine learning algorithms

squamous cell carcinoma

adenocarcinoma

detection sensitivity